The use of nanoparticulate pharmaceutical drug delivery systems (NDDSs) to enhance the
in vivo effectiveness of drugs is now well established. The development of multifunctional …

Dyslipidemia, characterized by a high level of lipids (cholesterol, triglycerides, or both), can
increase the risk of developing and progressing atherosclerosis. As atherosclerosis …

A significant limitation of cardiovascular stents is restenosis, where excessive smooth
muscle cell (SMC) proliferation following stent implantation causes blood vessel …

Atherosclerosis, a leading cause of mortality in developed countries, is characterized by the
buildup of oxidized low-density lipoprotein (oxLDL) within the vascular intima, unregulated …

Atherosclerosis, the build-up of occlusive, lipid-rich plaques in arterial walls, is a focal trigger
of chronic coronary, intracranial, and peripheral arterial diseases, which together account for …

Cardiovascular disease initiates with the atherogenic cascade of scavenger receptor-(SR-)
mediated oxidized low-density lipoprotein (oxLDL) uptake. Resulting foam cell formation …

Conspectus Various therapeutics exhibit unfavorable physicochemical properties or stability
issues that reduce their in vivo efficacy. Therefore, carriers able to overcome such …

Native nanostructured lipoproteins such as low-and high-density lipoproteins (LDL and
HDL) are powerful tools for the targeted delivery of drugs and imaging agents. While the …

Atherosclerosis is one of the leading causes of vascular diseases, with high morbidity and
mortality worldwide. Macrophages play a critical role in the development and local …

Coronary arterial disease, one of the leading causes of adult mortality, is triggered by
atherosclerosis. A disease with complex etiology, atherosclerosis results from the …